


# **FARMAKOTERAPI**

# **OBAT ANTIEPILEPSI**

**Fathiyah Safithri**  
**2024**


# DEFINISI

- Epilepsi → kejadian kejang /konvulsi /seizure yang terjadi spontan, episodik, berulang (kambuhan)
- Kejang /seizure : manifestasi klinis dari aktivitas neuron yang berlebihan di korteks serebral
- Manifestasi klinis kejang bervariasi tergantung daerah otak yang terlibat
- Fokus ektopik → neuron epileptik



Brain scan of a person with frontal lobe epilepsy. Arrow points to the focus of seizure activity. [Image reproduced with permission from Seck et al. (1998) *Electroenceph. Clin. Neurophys.* 106, 508-512.]

# SEIZURE




Kejang disebabkan krn :

- Ketidakseimbangan antara pengaruh inhibisi (GABA) dan eksitatori pada otak (Glutamat)
- **Me ↓ transmisi inhibitori** : paska Tx dg antagonis GABA, penghentian pemberian agonis GABA (benzodiazepin, alkohol)
- **Me ↑ transmisi eksitatori** : meningkatnya glutamat atau aspartat

# Penyebab seizure mnrt usia

<b>Age Range</b>	<b>Major Causes</b>
Infant	Birth injury, hypoxia/ischemia, congenital malformations, and congenital infection
Childhood	Febrile seizures, central nervous system infection, head trauma, birth injury, and idiopathic origin
Young adult	Head trauma, drugs, withdrawal from alcohol or sedatives, and idiopathic origin
Elderly	Strokes, brain tumor, cardiac arrest with hypoxia, and metabolic origin

# Etiologi Epilepsi



Primary - Idiopathic (77%)

- Primary - Idiopathic
- Cerebrovascular
- CNS Neoplasma
- Congenital CNS Malformation
- Trauma
- CNS Infection
- Other known
- Birth asphyxia




# Causes of Seizures

## Partial seizures




Hypoxia

JOHN A. CRAIG M.D.  
© CIBA-GEIGY



Depressed skull fracture


Tumor



Pus

Unknown or cryptogenic cause

Infection



Hemorrhage

Infarction

Cortical dysplasia (thick cortex)

Vascular malformation

Congenital abnormalities

## Generalized seizures



Abnormal neuronal seizure sensitivity



GABA

Abnormal quantity or quality of neurotransmitter or receptor



Metabolic disease

Genetic influences may predispose to seizure activity

Insecticides



Spray paint

Environmental toxins



Illicit and prescription drugs



Drug and alcohol use and withdrawal

# Causes of Seizures

## Primary



? Unknown (genetic or biochemical predisposition)

## Intracranial



Tumor



Vascular (infarct or hemorrhage)



Arteriovenous malformation



Trauma  
(depressed fracture,  
penetrating wound)




Infection  
(abscess,  
encephalitis)



Congenital and  
hereditary diseases  
(tuberous sclerosis)

## Extracranial

Metabolic  
Electrolyte  
Biochemical  
Inborn errors  
of metabolism




Anoxia  
Hypoglycemia  
Drugs  
Drug withdrawal  
Alcohol withdrawal

*F. Netter M.D.*  
© CIBA

# KLASIFIKASI EPILEPSI


Berdasarkan tanda klinik dan hasil EEG, kejang dibagi :

- **Kejang umum (genelized seizure) :** aktivasi terjadi pada kedua hemisfere otak secara bersama-sama
- **Kejang parsial / focal :** jika dimulai dari bagian tertentu di otak.





# ILAE 2017 Classification of Seizure Types Basic Version <sup>1</sup>




<sup>1</sup> Definitions, other seizure types and descriptors are listed in the accompanying paper & glossary of terms

<sup>2</sup> Due to inadequate information or inability to place in other categories

From Fisher et al. *Instruction manual for the ILAE 2017 operational classification of seizure types*. *Epilepsia* doi: 10.1111/epi.13671

# ILAE 2017 Classification of Seizure Types Expanded Version<sup>1</sup>



<sup>1</sup> Definitions, other seizure types and descriptors are listed in the accompanying paper and glossary of terms.

<sup>2</sup> These could be focal or generalized, with or without alteration of awareness

<sup>3</sup> Due to inadequate information or inability to place in other categories

From Fisher et al. *Instruction manual for the ILAE 2017 operational classification of seizure types*. *Epilepsia* doi:

# MEKANISME SEIZURE PD EPILEPSI

- **Neuron :**

Neuron epileptik mencetuskan letupan depolarisasi paroxysmal yg merubah potensial membran, berulang-ulang, IPSP hilang dan letupan depolarisasi abnormal menjalar ke sel sekitar

- **Kanal ion :**

Terjadi defect pada transmisi sinap antar neuron

# PRINSIP TERAPI EPILEPSI

- Mencegah penyebaran seizure ke neuron yang masih normal
- Meningkatkan nilai ambang neuron epileptik

Pd umumnya obat antikonvulsan dapat menghilangkan gejala (seizure) → 50%, sebagian seizure dapat ditekan sehingga tidak menyebar



# TATA LAKSANA EPILEPSI

- **Non – farmakologis**
  - cari dan hindari faktor pemicu (jika ada) : stress, OR, kopi, alkohol, sulit tidur, terlambat makan
- **Farmakologis :**
  - dengan obat antiepilepsi / antikonvulsi

# Generasi I- Antiepileptic drug

Drug*	Presumed main mechanism of action	Approved use (FDA, EMA)	Main uses	Main limitations
Potassium bromide (1857)	GABA potentiation?	Generalized tonic-clonic seizures, myoclonic seizures	Focal and generalized seizures	Currently for adjunctive use only, not in wide use anymore, sedative
Phenobarbital (1912)	GABA potentiation	Partial and generalized convulsive seizures, sedation, anxiety disorders, sleep disorders	Focal and generalized seizures (intravenous); most cost effective treatment for epilepsy, particularly in low resource countries	Enzyme inducer, not useful in absence seizures, skin hypersensitivity. Less effective than carbamazepine or phenytoin for focal seizures in mostly new onset epilepsy
Phenytoin (1938)	Na <sup>+</sup> channel blocker	Partial and generalized convulsive seizures	First line drug (intravenous) for focal and generalized seizures with focal onset; similar efficacy to carbamazepine <sup>42</sup>	Enzyme inducer, non-linear pharmacokinetics. Not useful for absence or myoclonic seizures; skin hypersensitivity
Primidone (1954)	GABA potentiation	Partial and generalized convulsive seizures	Focal and generalized seizures	Enzyme inducer, not useful in absence seizures, sedative, skin hypersensitivity. Less effective than carbamazepine or phenytoin for focal seizures in new onset epilepsy
Ethosuximide (1958)	T-type Ca <sup>2+</sup> channel blocker	Absence seizures	First line antiepileptic drug, no skin hypersensitivity. Use for absence seizures only. As effective as valproate for new onset absence seizures	Gastrointestinal adverse effects, insomnia, psychotic episodes

# Generasi II –Antiepileptic drug

Drug*	Presumed main mechanism of action	Approved use (FDA, EMA)	Main uses	Main limitations
Diazepam (1963)	GABA potentiation	Convulsive disorders, status epilepticus, anxiety, alcohol withdrawal	Intravenous use, no clinical hepatotoxicity, no skin hypersensitivity, use for focal and generalized seizures	Currently for adjunctive use and emergency use only, sedative, substantial tolerance (loss of efficacy)
Carbamazepine (1964)	Na <sup>+</sup> channel blockade	Partial and generalized convulsive seizures, trigeminal pain, bipolar disorder	First line drug for focal and generalized seizures with focal onset; none of the newer drugs has currently been shown to be more efficacious than carbamazepine	Enzyme inducer, not useful for absence or myoclonic seizures, skin hypersensitivity
Valproate (1967)	Multiple (for example, GABA potentiation, glutamate (NMDA) inhibition, sodium channel and T-type calcium channel blockade)	Partial and generalized convulsive seizures, absence seizures, migraine prophylaxis, bipolar disorder	First line drug (used intravenously) for focal and generalized seizures; none of the newer drugs has currently been shown to be more efficacious than valproate; no skin hypersensitivity	Enzyme inhibitor, substantial teratogenicity, weight gain
Clonazepam (1968)	GABA potentiation	Lennox-Gastaut syndrome, myoclonic seizures, panic disorders	No clinical hepatotoxicity, use for focal and generalized seizures	Currently for adjunctive use only, sedative, substantial tolerance (loss of efficacy)
Clobazam (1975)	GABA potentiation	Lennox-Gastaut syndrome, anxiety disorders	No clinical hepatotoxicity. Use for focal and generalized seizures	Currently for adjunctive use only, sedative, substantial tolerance (loss of efficacy)



# Generasi III- Antiepileptic drug (1)

Drug*	Presumed main mechanism of action	Approved use (FDA, EMA)	Main uses	Main limitations
Vigabatrin (1989)	GABA potentiation	Infantile spasms, complex partial seizures (currently for adjunctive use only)	No clinical hepatotoxicity. Use for infantile spasms, focal and generalized seizures with focal onset	Not useful for absence or myoclonic seizures. Causes a visual field defect and weight gain. Not as efficacious as carbamazepine for focal seizures
Lamotrigine (1990)	Na <sup>+</sup> channel blocker	Partial and generalized convulsive seizures, Lennox-Gastaut syndrome, bipolar disorder	First line drug for focal and generalized seizures	Enzyme inducer, skin hypersensitivity. Not as effective as valproate for new onset absence seizures
Oxcarbazepine (1990)	Na <sup>+</sup> channel blocker	Partial seizures	First line drug for focal and generalized seizures with focal onset	Enzyme inducer, hyponatremia, skin hypersensitivity. Not useful for absence or myoclonic seizures
Gabapentin (1993)	Ca <sup>2+</sup> blocker ( $\alpha 2\delta$ subunit)	Partial and generalized convulsive seizures, postherpetic and diabetic neuralgia, restless leg syndrome	No clinical hepatotoxicity. Use for focal and generalized seizures with focal onset	Currently for adjunctive use only. Not useful for absence or myoclonic seizures and can cause weight gain. Not as effective as carbamazepine for new onset focal seizures
Topiramate (1995)	Multiple (GABA potentiation, glutamate (AMPA) inhibition, sodium and calcium channel blockade)	Partial and generalized convulsive seizures, Lennox-Gastaut syndrome, migraine prophylaxis	First line drug for focal and generalized seizures. No clinical hepatotoxicity	Cognitive side effects, kidney stones, speech problems, weight loss. Not as effective as carbamazepine for new onset focal seizures
Levetiracetam (2000)	SV2A modulation	Partial and generalized convulsive seizures, partial seizures, GTCS, juvenile myoclonic epilepsy	First line drug (intravenous) for focal and generalized seizures with focal onset and myoclonic seizures. No clinical hepatotoxicity. As efficacious as carbamazepine for new onset focal seizures	Not useful for absence or myoclonic seizures. Psychiatric side effects




# Generasi III- Antiepileptic drug (2)

Drug*	Presumed main mechanism of action	Approved use (FDA, EMA)	Main uses	Main limitations
Zonisamide (2000)	Na <sup>+</sup> channel blocker	Partial seizures	First line drug for focal and generalized seizures. No clinical hepatotoxicity. Non-inferior to carbamazepine for new onset focal seizures	Cognitive side effects, kidney stones, sedative, weight loss
Stiripentol (2002)	GABA potentiation, Na <sup>+</sup> channel blocker	Dravet syndrome	Use for seizures in Dravet syndrome. No clinical hepatotoxicity	Currently for adjunctive use only
Pregabalin (2004)	Ca <sup>2+</sup> blocker ( $\alpha 2\delta$ subunit)	Partial seizures, neuropathic pain, generalized anxiety disorder, fibromyalgia	Use for focal and generalized seizures with focal onset. No clinical hepatotoxicity	Currently for adjunctive use only, not useful for absence or myoclonic seizures, weight gain
Rufinamide (2004)	Na <sup>+</sup> channel blockade	Lennox-Gastaut syndrome	Use for seizures in Lennox-Gastaut syndrome. No clinical hepatotoxicity	Currently for adjunctive use only
Lacosamide (2008)	Enhanced slow inactivation of voltage gated Na <sup>+</sup> channels	Partial seizures	Use (intravenous) for focal and generalized seizures with focal onset. No clinical hepatotoxicity	Currently for adjunctive use only
Eslicarbazepine acetate (2009)	Na <sup>+</sup> channel blocker	Partial seizures	Use for focal and generalized seizures with focal onset	Currently for adjunctive use only, enzyme inducer, hyponatremia
Perampanel (2012)	Glutamate (AMPA) antagonist	Partial seizures	Use for focal and generalized seizures with focal onset	Currently for adjunctive use only. Not useful for absence or myoclonic seizures

# Prinsip Mekanisme kerja Antiepilepsi


- ❑ Me ↑ transmisi inhibitory GABA-ergik
  - a. increase GABA
  - c. release GABA ↑
  - d. increase post sinap GABA activity
  - f. inhibit re-uptake GABA (blok GAT-1)
  - g. GABA-Agonist
- ❑ Me ↓ transmisi glutamate
  - b. relase glutamate ↓
  - e. block AMPA receptor
- ❑ Stabilisation of neuron
  - h. inhibition Na channel -  
prolong the inactivated stage
  - i. block Ca channel
- ❑ Lain-lain
  - j. Activates K channel
  - k. Block SV A
  - l. CRMP-2 inhibitor



DRUG		↑ GABA activity	↓ Glutamate Activity	Prolong inactivated Na <sup>+</sup> channels	Block T-Ca <sup>2+</sup> Channels	Other
1.	Phenytoin			✓		
2.	Carbamazepine			✓		
3.	Valproate	✓ (a)		✓	✓	
4.	Lamotrigine		✓ (b)	✓		
5.	Ethosuximide				✓	
6.	Gabapentin	✓ (c)				
7.	Topiramate	✓ (d)	✓ (e)	✓		Activates K <sup>+</sup> Channel
8.	Tiagabine	✓ (f)				
9.	Phenobarbitone	✓ (g)				
10.	Primidone	✓ (g)				
11.	Benzodiazepines	✓ (g)				
12.	Felbamate		✓ (h)			
13.	Levetiracetam					Block SV <sub>2</sub> A
14.	Zonisamide			✓	✓	
15.	Lacosamide			✓		CRMP-2 inhibitor
16.	Rufinamide			✓		
17.	Retigabine (Ezogabine)					K <sup>+</sup> channel opener




# SODIUM CHANNEL BLOCKER



Na terhambat masuk → meningkatkan keadaan steady state-inactivation → tdk terj aksi potensial :

**Fenitoin, Karbamazepin, Valproat,, Lamotrigin, Topiramamat, Lacosamide**

# Phenytoin




## Action of phenytoin on Na channel

- (A) Resting state in which Na channel activation gate (A) is closed
  - (B) Arrival of an action potential causes depolarization and opening of activation gate (A) and Na flows into the cell.
  - (C) When depolarization continues, an inactivation gate (B) moves into the cell.
- Phenytoin prolongs the inactivated gate of the Na channel by preventing the reopening of inactivation gate (B).

# Phenytoin (Drug induced gingival overgrowth/hyperplasia)

https://out




Oral Dis 2015 Jan;21(1):e51-61.  
doi: 10.1111/odi.12264. Epub 2014 Aug 7.

Mechanism of drug-induced gingival overgrowth revisited: a unifying hypothesis


[R.S. Brown](#)<sup>1</sup>, [P.R. Arany](#)

# Intoksikasi Fenitoin





# CALCIUM CHANNEL BLOCKER



Blok kanal Ca → menurunkan ' the low-threshold calcium current (LTCC) ' atau ' T (transient) current'

**Valproat, Ethosuximide, Dimethadione, Lamotrigin**  
**Utk absence seizure, petit mall epilepsy**


# Valproic acid

## Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences

**Author(s):** Michele Romoli, Petra Mazzocchetti, Renato D'Alonzo, Sabrina Siliquini, Victoria Elisa Rinaldi, Alberto Verrotti, Paolo Calabresi and Cinzia Costa\* Volume 17 , Issue 10 , 2019


**Page:** [926 - 946] **Pages:** 21


**DOI:** [10.2174/1570159X17666181227165722](https://doi.org/10.2174/1570159X17666181227165722)



# Valproic acid (VPA)


- VPA blocks the action of histone deacetylases (HDACs) and leads to transcriptional activation of anti-apoptotic and neuronal surviving pathways like HSP70, AKT, CDK5, ERK, NF- $\kappa$ B, and suppression of caspase-3, TNF- $\alpha$ , IL-1 $\beta$ , IL-6, ROS, and many other factors which cause neuronal death.





**Anticancer activity** →

- Inhibition of cell proliferation
- Induction of apoptosis
- Suppression of NF-κB
- Activation of p53 and PTEN



**Anti-inflammatory activity**

**Cardioprotective activity** →



Protection against cardiac dysfunction

**Antimicrobial activity**

**Neuroprotective activity** →



Protection against neurodegeneration

**Antidiabetic activity**

**Nephroprotective activity** →



Protection against renal injury

**Other activity** →

- Inhibition of retinal injury
- Protection against pulmonary injury
- Molecular docking studies





# Me ↑ transmisi GABA





Figure 8.14 GABA reuptake and resynthesis. On the left, GABA molecules are being recycled intact. On the right, GABA is taken up by an astrocyte, then (1) GABA is converted to glutamate by GABA transaminase. (2) Glutamate is converted to glutamine by glutamine synthetase. (3) Glutamine is taken up by the axon and converted to glutamate by glutaminase. (4) Glutamate is converted to GABA by glutamate decarboxylase and (5) returned to a synaptic vesicle.




# Ionotropic GABA Receptors



- Pentamers
- Inhibitory in action because the associated channels are permeable to negatively charged  $\text{Cl}^-$  ions
- Benzodiazepines are allosteric modulators to GABA neurotransmission


# Me ↑ transmisi GABA

## B Inhibitory synapse




- **Agonis GABA :**
  - **Phenobarbital** : mengikat allosteric site GABA-barbiturat receptor → meningkatkan aksi GABA-inhibitori : memperpanjang lama terbukanya kanal Cl → hiperpolarisasi,
  - **Benzodiazepin** : mengikat allosteric site GABA-benzodiazepine receptor → aktivasi R/ GABA : me ↑ frekuensi pembukaan kanal ion Cl → hiperpolarisasi
- Me ↑ kdr GABA dlm CSF, mungkin dg menstimuli release GABA dr non vesikuler pool , Analog GABA, agonis GABA<sub>B</sub>,  
: **Gabapentin**
- **Memfasilitasi** glutamic acid decarboxylase (GAD), the enzyme responsible for GABA synthesis : **Valproate**
- **menghambat re-uptake GABA ke neuron & glia** → GABA di sinap lebih lama : **Tiagabin**
- **Hambat enzim metab GABA-transaminase** → konsentr GABA ↑(GABA-T) : **Vigarabin, Valproate**

# Me ↑ transmisi GABA






# GLUTAMATE NEUROTRANSMISSION



# MENGHAMBAT AKSI GLUTAMAT


- Blok R/ NMDA → aksi Glutamat-eksitatori terhambat **Phenobarbital,**  
**Valproic**
- menurunkan release glutamat di sinap : **Lamotrigine**
- Blok R/ kainate: **Topiramate**

# Synaptic Vesicle Glycoprotein 2A



# Levetiracetam

- **modulation of synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A in the brain.** reduce excitatory neurotransmitter release and enhance synaptic depression during trains of high-frequency activity






**Table 3** Mechanisms of action of anticonvulsant drugs<sup>a</sup>


Drug	Blocks Na <sup>+</sup> channels	Blocks CA <sup>2+</sup> channels	GABA agonist	Blocks NMDA	Blocks other glutamate
Phenobarbital			◆		
Phenytoin	◆				
Carbamazepine	◆				
Ethosuximide		◆			
Valproate	◆	◆			
Felbamate	◆		◆	◆	◆
Gabapentin			??		??
Lamotrigine	◆				◆
Topiramate	◆		◆		◆

<sup>a</sup>GABA, Gamma-aminobutyric acid; NMDA, N-methyl-D-aspartic acid.

excitatory  
presynaptic  
terminal



postsynaptic  
neuron




# DOC bdsr klasifikasi epilepsi

	Kejang parsial	Kejang Umum (generalized seizures)		
		Tonic-clonic	Abscense	Myoclonic, atonic
<b>Drug of choice</b>	<b>Karbamazepin Fenitoin Valproat</b>	<b>Valproat Karbamazepin Fenitoin</b>	<b>Etosuksimid Valproat</b>	<b>Valproat</b>
Alternatives	Lamotrigin Gabapentin Topiramate Tiagabin Primidon Fenobarbital	Lamotrigin Topiramate Primidon Fenobarbital	Clonazepam Lamotrigin	Klonazepam Lamotrigin Topiramate Felbamat



Seizure Type	First-line	Second-line	Third-line
<b>Generalized Seizures</b>			
Absence (typical and atypical)	Valproate	Ethosuximide Lamotrigine	Levetiracetam Zonisamide
Myoclonic	Valproate	Topiramate Levetiracetam Lamotrigine Zonisamide	Clobazam Clonazepam Phenobarbital
Tonic-clonic	Phenobarbital Phenytoin Carbamazepine Valproate	Lamotrigine Oxcarbazepine	Topiramate Levetiracetam Zonisamide
Atonic	Valproate	Lamotrigine Topiramate	Felbamate
<b>Partial Seizures</b>			
Simple and complex partial with or without secondary generalization	Phenobarbital Phenytoin Carbamazepine	Valproate Oxcarbazepine Lamotrigine Topiramate Levetiracetam Zonisamide	Gabapentin Tiagabine Vigabatrin Felbamate

RESPONSE TO ANTI-EPILEPTIC DRUGS



# Pemilihan OAE Berdasarkan Tipe Bangkitan

Tipe Bangkitan	Lini Pertama	Apabila tidak cocok terhadap lini pertama	OAE Tambahan dari OAE lini pertama	Apabila tidak cocok terhadap OAE tambahan dapat diganti	Dapat memperburuk bangkitan
<b>Bangkitan Absans</b>	Ethosuximide, Sodium Valproate	Lamotrigine	Kombinasi 2 dari 3 OAE : Ethosuximide, Lamotrigine, Sodium Valproate	clobazam, Clonazepam, Topiramate, Levetiracetam, Zonisamide.	Carbamazepine, Gabapentine, Oxcarbazepine, Phenytoin, Pregabalin, Tiagabin, Vigabatrine
<b>Bangkitan General Tonik Klonik</b>	Sodium Valproate	Lamotrigine	Clobazam, Lamotrigine, Levetiracetam, Sodium Valproate, Topiramate		

# Pemilihan OAE Berdasarkan Tipe Bangkitan

Tipe Bangkitan	Lini Pertama	Apabila tidak cocok terhadap lini pertama	OAE Tambahan dari OAE lini pertama	Apabila tidak cocok terhadap OAE tambahan dapat diganti	Dapat memperburuk bangkitan
<b>Bangkitan Fokal</b>	Carbamazepine, Lamotrigine	Levetiracetam, oxcarbazepine, Sodium Valproate	Carbamazepine, Clobazam, Gabapentin, Lamotrigine, Levetiracetam, Oxcarbazepine, Sodium Valproate, Topiramate.	Eliscarbazepine acetate, Lacosamide, Phenobarbital, Phenytoin, Pregabalin, Tiagabine, vigabatrine, Zonisamide.	
<b>Bangkitan Myoklonik</b>	Sodium Valproate.	Levetiracetam, Topiramate.	Levetiracetam, Sodium valproate, Topiramate.	Clobazam, Clonazepam, Piracetam, Zonisamide.	Carbamazepine, Gabapentin, Oxcarbazepine, Phenytoin, Pregabalin, Tiagabine, Vigabatrine.

# First line Drug

- **New onset partial epilepsies**

Carbamazepine

Gabapentin

Lamotrigine

Levetiracetam

Oxcarbazepine

Topiramate

Valproate

- **New onset idiopathic generalized epilepsies**

Lamotrigine

Topiramate

Valproate

- **Refractory partial epilepsy**

Lacosamide

Pregabalin

Zonisamide

Perampanel

Clobazam

- **Refractory idiopathic generalized epilepsies**

Clobazam

Levetiracetam



# Side Effect – Early Onset

Adverse effect	CBZ	CLB	ESL	ETS	FBM	GBP	LCM	LEV	LTG	OXC	PGN	PER	PHB	PHT	TGB	RTG	TPM	VPA	VGB	ZNS	
EARLY ONSET ADVERSE EVENTS																					
Somnolence	-	●	●	●	-	●	●	●	●	-	●	-	●	-	●	●	●	-	●	●	
Dizziness	-	●	-	●	-	●	●	●	●	●	-	-	-	●	●	-	●	-	●	●	
Seizure aggravation	●	●	●	-	-	●	-	-	-	-	●	-	-	●	●	-	-	-	●	-	
Gastrointestinal	●	-	-	●	●	●	-	●	-	●	-	-	-	-	-	-	-	●	-	●	
Hypersensitivity (SJS/ TEN)	●	-	●	●	●	-	-	-	●	●	-	-	●	●	-	-	●	-	-	●	
Rash	●	-	-	-	-	-	-	-	●	●	-	-	-	●	-	-	-	-	-	-	

CLB=clobazam; CBZ=carbamazepine; ESL=eslicarbazepine; ETS=ethosuximide; FBM=felbamate; GBP=gabapentin; LEV=levetiracetam; LCM=lacosamide; LTG=lamotrigine; OXC=oxcarbazepine; PER=perampanel; PGB=pregabalin; PHB=phenobarbital; PHT=phenytoin; PRM=primidone; RTG=retigabine; ; TPM=topiramate; VPA=valproate; VGB=vigabatrin; ZNS=zonisamide; SJS/TEN=Stevens-Johnson syndrome or toxic epidermal necrolysis. Key: - no increase, ● low risk, ● medium risk, ● high risk

# Side Effect - Late Onset (1)

Adverse effect	CBZ	CLB	ESL	ETS	FBM	GBP	LCM	LEV	LTG	OXC	PGN	PER	PHB	PHT	TGB	RTG	TPM	VPA	VGB	ZNS
Encephalopathy														●				●	●	
Depression				●									●	●	●				●	
Behavioral problems								●				●	●	●	●		●		●	●
Psychotic episodes	●			●	●	●		●					●	●	●		●	●	●	
Leukopenia	●			●	●					●			●	●						
Aplastic anemia	●			●	●								●	●						
Thrombocytopenia					●														●	
Megaloblastic anemia	●												●	●						
Pancreatitis						●													●	
Liver failure					●														●	

CLB=clobazam; CBZ=carbamazepine; ESL=eslicarbazepine; ETS=ethosuximide; FBM=felbamate; GBP=gabapentin; LEV=levetiracetam; LCM=lacosamide; LTG=lamotrigine; OXC=oxcarbazepine; PER=perampanel; PGB=pregabalin; PHB=phenobarbital; PHT=phenytoin; PRM=primidone; RTG=retigabine; ; TPM=topiramate; VPA=valproate; VGB=vigabatrin; ZNS=zonisamide; SJS/TEN=Stevens-Johnson syndrome or toxic epidermal necrolysis. Key: – no increase, ● low risk, ● medium risk, ● high risk

# Side Effect - Late Onset (2)

Adverse effect	CBZ	CLB	ESL	ETS	FBM	GBP	LCM	LEV	LTG	OXC	PGN	PER	PHB	PHT	TGB	RTG	TPM	VPA	VGB	ZNS
Nephrolithiasis																	●			●
Osteoporosis	●												●	●				●		
Hyponatremia	●		●							●										
Weight gain	●					●					●							●	●	
Weight loss					●												●			●
Cognition impaired	●	●	●										●	●			●			●
Teratogenicity																	●	●		
Retinal dysfunction																●		●		

CLB=clobazam; CBZ=carbamazepine; ESL=eslicarbazepine; ETS=ethosuximide; FBM=felbamate; GBP=gabapentin; LEV=levetiracetam; LCM=lacosamide; LTG=lamotrigine; OXC=oxcarbazepine; PER=perampanel; PGB=pregabalin; PHB=phenobarbital; PHT=phenytoin; PRM=primidone; RTG=retigabine; TPM=topiramate; VPA=valproate; VGB=vigabatrin; ZNS=zonisamide; SJS/TEN=Stevens-Johnson syndrome or toxic epidermal necrolysis. Key: - no increase, ● low risk, ● medium risk, ● high risk

**Table 2** Dosing and pharmacokinetics of anticonvulsant drugs

Drug	Usual adult dose 24 h (mg)	Half-life (h)	Usually effective plasma concentration ( $\mu\text{g/mL}$ )	Time to peak concentration (h)	Bound fraction (%)
Phenytoin	300–400	22	10–20	3–8	90–95
Carbamazepine	800–1600	8–22	8–12	4–8	75
Phenobarbital	90–180	100	15–40	2–8	45
Valproate	1000–3000	15–20	50–120	3–8	80–90
Ethosuximide	750–1500	60	40–100	3–7	<5
Felbamate	2400–3600	14–23	20–140		25
Gabapentin	1800–3600	5–7	>2 <sup>a</sup>	2–3	<5
Lamotrigine	100–500	12–60 <sup>b</sup>	1–4 <sup>a</sup>	2–5	55
Topiramate	200–400	19–25 <sup>b</sup>	NE <sup>c</sup>	2–4	9–17
Vigabatrin	1000–3000	5–7	NE	1–4	5
Tiagabine	32–56	5–13	NE	1	95

<sup>a</sup>Not established; corresponds to usual range in patients treated with recommended dose.

<sup>b</sup>Highly dependent on concurrently administered drugs.


<sup>c</sup>NE, Not established.





# ANTIEPILEPTIC IN CHILD

\*Multiple mechanisms of action



## Antiepileptic Drugs of Choice for Treatment of Generalized Seizures in Children

GTC	Absence	Myoclonic	Tonic	Atonic
<b><i>First Choice</i></b>				
Valproate	Ethosuximide Lamotrigine Valproate	Valproate	Lamotrigine Valproate	Lamotrigine valproate
<b><i>Second choice</i></b>				
Carbamazepine	Lavetiracetam	Clonazepam	Phenytoin	Lamotrigine
Phenytoin	Topiramate	Levetiracetam	Topiramate	Topiramate
Topiramate	Zonisamide	zonisamide	Felbamate	Felbamate

# Antiepileptic Drugs of Choice for Treatment of Focal Seizures in Children

## *First choice*

Carbamazepine

## *Second choice*

Valproate

Phenytoin

Phenobarbital

Lamotrigine

## *Alternative agent*

Gabapentin

Lamotrigine

Oxcarbamazepine

topiramate



# Prinsip Terapi dg Antiepilepsi

- **monoterapi** lebih baik → mengurangi potensi *adverse effect*, meningkatkan kepatuhan pasien, tidak terbukti bahwa politerapi lebih baik dari monoterapi
- hindari atau minimalkan penggunaan **antiepilepsi sedatif** → toleransi, efek pada intelegensia, memori, kemampuan motorik bisa menetap selama pengobatan
- jika mungkin, mulai terapi dgn satu **antiepilepsi non-sedatif**, jika gagal baru diberi sedatif atau politerapi
- berikan terapi **sesuai dgn jenis epilepsinya**

# Prinsip Terapi dg Antiepilepsi

- mulai dengan **dosis terkecil** dan dapat ditingkatkan sesuai dg kondisi klinis pasien → penting : kepatuhan pasien
- ada **variasi individual** terhadap respon obat antiepilepsi → perlu pemantauan ketat dan penyesuaian dosis
- jika suatu obat gagal mencapai terapi yang diharapkan → pelan-pelan dihentikan dan diganti dengan obat lain (jgn politerapi)
- lakukan monitoring kadar obat dalam darah → jika mungkin, lakukan penyesuaian dosis dgn melihat juga kondisi klinis pasien

# **Prinsip Terapi dg Antiepilepsi**

# ALGORITMA TATALAKSANA EPILEPSI

Diagnosa positif

Mulai pengobatan dg satu AED  
Pilih berdasar klasifikasi kejang  
dan efek samping

Ya

Sembuh ?

Tidak

Efek samping dapat ditoleransi ?

Efek samping dapat ditoleransi ?

Ya

Tidak

Ya

Tidak

Kualitas hidup optimal ?

Turunkan dosis

Tingkatkan dosis

Turunkan dosis  
Tambah AED 2

Ya

Tidak

Pertimbangkan,  
Atasi dg tepat

Hentikan AED 1  
Tetap gunakan  
AED 2

Sembuh ?

Ya

Tidak

Lanjutkan  
terapi

lanjut

lanjut



lanjutan



# STATUS EPILEPTIKUS

- kejang umum yang terjadi selama 5 menit atau lebih atau kejadian kejang 2 kali atau lebih tanpa pemulihan kesadaran di antara dua kejadian tersebut
- Merupakan kondisi darurat yg memerlukan pengobatan yang tepat untuk meminimalkan **kerusakan neurologik permanen** maupun kematian

# Penyebab Status Konvulsi

## Tipe 1

(tidak ada lesi struktural)

- Infeksi
- Infeksi CNS
- Gangguan metabolik
- Turunnya level AED
- Alkohol
- Idiopatik

## Tipe 2

( Ada lesi struktural)

- Anoksia/hipoksia
- Tumor CNS
- CVA
- Overdose obat
- Hemoragi
- Trauma

# TATA LAKSANA STATUS KONVULSI

- **Non-farmakologi:**

- Tanda-tanda vital dipantau
- Perhatikan ventilasi
- Berikan oksigen
- Cek gas darah utk memantau asidosis respiratory atau metabolik
- Kadang terjadi hipoglikemi → berikan glukosa

- **Farmakologi : dengan obat-obatan**



# Status epilepticus

Initial therapy (dalam 5 menit)	
Dewasa	Anak
Midazolam im Lorazepam iv Diazepam iv Phenobarbital iv	Lorazepam iv Diazepam iv Diazepam rectal Midazolam im/nasal/buccal
Sama efektifnya	Sama efektifnya (Lv A) (Lv B)
Bila belum terpasang iv line: midazolam im lebih superior	

Kejadian depresi napas dan kardiovaskuler lebih tinggi pada status epilepticus untreated dibandingkan dengan pemberian initial therapy → PENTING !

American Epilepsy Society, 2016

Pasien epilepsi dengan riwayat status epilepticus memanjang/berulang, disiapkan midazolam buccal/ diazepam rectal (NICE, 2012)

# Algoritma status epilepticus

From "Treatment of Convulsive Status Epilepticus in Children and Adults," *Epilepsy Currents* 16.1 - Jan/Feb 2016

## Time Line

0-5 Minutes  
Stabilization  
Phase


## Interventions for emergency department, in-patient setting, or prehospital setting with trained paramedics

1. Stabilize patient (airway, breathing, circulation, disability - neurologic exam)
2. Time seizure from its onset, monitor vital signs
3. Assess oxygenation, give oxygen via nasal cannula/mask, consider intubation if respiratory assistance needed
4. Initiate ECG monitoring
5. Collect finger stick blood glucose. If glucose < 60 mg/dl then  
Adults: 100 mg thiamine IV then 50 ml D50W IV  
Children ≥ 2 years: 2 ml/kg D25W IV Children < 2 years: 4 ml/kg D12.5W IV
6. Attempt IV access and collect electrolytes, hematology, toxicology screen, (if appropriate) anticonvulsant drug levels

0-10 menit

## Prehospital

Prehospital → primary survey  
Diazepam supp 10-20 mg, dapat diulang 15 menit



**5-20 Minutes  
Initial Therapy  
Phase**


Midazolam im 10 mg (single dose)  
 Diazepam iv (0,15-2 mg/kg BB, max 10 mg) (may repeat once)

**SE Dini**

0-30 menit

Diazepam iv (0,15-2 mg/kg BB, max 10 mg) (may repeat once)  
 OAE yang rutin dikonsumsi diberikan

**20-40 Minutes  
Second Therapy  
Phase**



Phenytoin 15-18 mg/kg, kecepatan maksimal 50 mg/menit

1 ampul = 100 mg (50 kg → 8 ampul, minimal dalam 16 menit)

**SE Menetap**

0-60 menit

Phenytoin 15-18 mg/kg, kecepatan maksimal 50 mg/menit  
Atau  
Phenobarbital 10-15 mg/kg iv kecepatan 100 mg/menit



**40-60 Minutes  
Third Therapy  
Phase**




**SE Refrakter**

30-90 menit


**ICU**

Konsul Anestesi

Terapi: Propofol, midazolam, thiopental → dipertahankan 12-24 jam sampai bangkitan klinis/elektrografis terakhir, tapering off



# TREATMENT OF GENERALIZED TONIC-CLONIC STATUS EPILEPTICUS IN ADULTS





TERIMA KASIH..